AMR policy in Belgium

First experiences with implementing Council recommendations on AMR




Health Food Chain Safety Environment



Background: Belgian (Federal) AMR policy

- 1999: Belgian AntiBiotics COordination Commission (BAPCOC)
 - AMR policy in hospitals and community sector
 - Guidance on AMS and IPC
- 2012: AMCRA
 - Co-governance by government agencies and animal sectors
 - Guidance on AMS and IPC
 - Tailored reduction targets
 - Convenant







2

Figure 4. Total national sales of antibacterial compounds for veterinary use in Belgium for the years 2011-2022 (tonnes antibacterial active substance).

Background: Policy evaluation & support (2017-2019)

EUROPEAN COMMISSION DIRECTORATE-SENERAL FOR HEALTH AND FOOD SAFETY Health and food audits and analysis

REFERENCES: ECDC, BELGIUM, COUNTRY VISIT AMR. STOCKHOLM: ECDC; 2017 DG(SANTE)/2017-6293 EXECUTIVE SUMMARY OF A COUNTRY VISIT TO BELGIUM FROM 16 TO 24 NOVEMBER 2017

TO DISCUSS POLICIES RELATING TO ANTIMICROBIAL RESISTANCE IN A ONE HEALTH PERSPECTIVE

NB: THIS IS AN EXECUTIVE SUMMARY BASED ON THE FOLLOWING ECDC AND COMMISSION REPORTS: BEGUW, COUNTRY VISIT AMR. STOCKHOLM: ECDC; 2017. https://ecdc.europa.eu/en/publications-data/ecdc-country-visit-beglum-discuss-antimicrc DG/SANTE//2017-6293 http://ec.cumons.tu/roco/subtrs-antirys/subtr_apports/impex.cm

IT HAS BEEN PROVIDED TO ASSIST VISITORS TO THIS SITE, BUT HAS NO OFFICIAL STATUS. REFI BE MADE TO THE FULL TEXT OF THE ORIGINAL REPORTS. Federal Kennicertrem rear de General-Center Féderal d'Experies des Soins de

SHORT REPORT

KCE REPORT 311Cs

Ref. Ares/2018)3848404 - 09/07/2018

ecoc

PROPOSALS FOR A MORE EFFECTIVE ANTIBIOTIC POLICY IN BELGIUM



• Main issues

- Lack of long-term efficacy in human sector
- Lack of focus on Ambulatory care and Long-term care facilities
- Lack of attention to companion animals
- Lack of focus on prescriber behaviors
- Lack of One Health perspective





NAP AMR 2020-2024



- Continuation of current actions in human and animal health
- Focus on infection prevention and stewardship
- Inclusion of Environment
- Transversal focus and governance





Main issues with Current NAP

- Problems on paper
 - Patel et al. (2023)

					Policy design								Implementation tools							Monitoring and evaluation			
	Governance score	Policy design	Implementation tools	Monitoring and evaluation	Strategic vision	Coordination	Participation	Accountability	Transparency	Sustainability	Equity	Surveillance	Antimicrobial stewardship	Infection prevention and control	Education	Public awareness	Medicines regulation	R esearch and development for novel products	Reporting	Feedback mechanism	Effectiveness	Antimicrobial resistance research	
Norway	85	76	92	87	72			50	88	50				81	64		100		83	67		100	
USA	84	83	85	83	97	96	94	50	88	72		86	81	96	64	90	75	100	83	50	100	100	
ик	83	85	80	88	95	100	100	50	88	75	100	99	70	94	42	58	100	100	96	50	100	100	
Sweden	78	69	87	76	72	96	94	50	88	47	0	100	91	73	56	93	100		83	17	100	100	
Denmark	76	85	75	57	94	100	100	67	100	75	0	83	83	81	64	93	83	33	100	58	0	50	
Germany	76	74	79	69	39			50	88	75		96	80	77	47	56	100		92	33	50	88	
Japan	75	67	84	71	93	96	89	50	63	45	0	81	83	96	44	93	92		92	33	100	50	
Australia	75	76	70	89	60	100	100	50	88	75	50	75	57	94	42	56	67	100	83	75	100	100	
Switzerland	75	79	71	74	72		94	83	88	74	0	80	74	75	42	56	83	83	96	50	100	38	
France	74	73	82	55	97	92	72	50	88	39	100	86	93	92	61	79	83	67	83	33	50	38	
Malaysia	73	66	85	60	70	96	94	50	63	47	50	99	99	92	64	95	83	50	83	83	50	13	
South Korea	73	72	73	71	91	100	100	50	63	50	50	83	92	96	28	63	67	67	54	75	100	63	
Thailand	72	72	69	80	89	100	100	50	63	50	50	92	78	94	42	88	75	0	83	83	50	100	
Netherlands	71	63	88	48	41	96	94	50	88	47	0	92	91	98	47	98	83	100	79	33	0	63	
Philippines	71	76	68	71	81	96	83	50	75	69	100	64	79	85	28	54	67	83	38	75	100	88	
Spain	71	61	82	64	67	69	83	56	75	37	0	93	93	88	47	90	75	83	67	50		38	
Austria	70	64	86	43	64		100	50	63	50	0	95	88	88	61	95	92	83	92	42	0	13	
Ireland	69	77	62	72	88	77	89	39	88	67	100	87	53	96	42	14	67	67	83	50	100	50	
Singapore	66	58	68	79	45	96	89	50	63	45	0	85	76	85	25	58	50	83	92	17		100	
Greece	65	63	74	46	33	96	89	50	75	70	0	83	88	88	69	56	83	33	58	58	0	63	
Italy	65	66	66	59	95	63	94	28	88	43	0	74	83	81	42	54	75	33	96	58	50	13	
China	64	61	80	27	86	100	83	33	50	46	0	82	90	79	28	83	92	100	42	33	0	25	
Belgium	63	62	68	51	38		100	50	75	50	0	84	73	100	47	26	100	33	83	92	0	13	
Latvia	63	52	72	62	59	35	83	17	75	46	0	84	74	92	42	51	75	83	38	33	100	88	

• Problems in Practice

• Court of Audit (2022)

Focus on Ambulatory care



Beleid inzake het voorschrijven en afleveren van antibiotica



International support for AMR

- Academics/ECDC • e.g. et al 2019
- WHO/Europe Roadmap AMR
- European Council Recomendations
- EU-JAMRAI-2



EU-144




Figure 2: Antimicrobial resistance governance framework with three areas and 18 domains







- Updating process of NAP
- Participating in EU-JAMRAI-II
- Cooperation (H) and governance (A1B)





- Updating process of NAP
 - Including consumption targets as targets and monitoring criteria (A1c, E15, E21)
 - Role of availability/access in AMR policy (G)
 - → Clear help in Council recommendations
 - Work on Programme theory of NAP
 - Set up clear targets for prioritization of actions
 - Flexible updating, based on emerging evidence and guidance (A3)

→ Limited guidance in Council recommendations





- Participation in EU-JAMRAI-II
 - Participation Across all WP's
 - Participation from different actors
 - Across sector (Government, Research institutes, Sector organisations)
 - Across Federal level and federated entities
 - Close coordination with NAP
 - Facilitated by participation in WP5







- Coöperation (H) and governance (A1B)
 - Implementation issues
 - Balancing transversal goals and sectoral specificity
 - Need for further guidance & support



